Form 4: IN8BIO CEO William Ho Granted 206,000 Stock Options

IN8BIO's CEO, William Tai-Wei Ho, was granted 206,000 employee stock options with an exercise price of $1.96, vesting over four years.

Summary

• William Tai-Wei Ho, CEO, Director, and 10% Owner of IN8BIO, INC. (INAB), was granted 206,000 employee stock options.
• The transaction date for this grant was February 4, 2026.
• The exercise price for these stock options is $1.96 per share.
• The options will vest over time, with 25% vesting on February 4, 2027, and the remaining shares vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon Mr. Ho continuing to provide service to the company.
• The expiration date for these options is February 4, 2036.
• Following this transaction, Mr. Ho beneficially owns 206,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strengthens the alignment of the CEO's long-term incentives with shareholder value, though it does not reflect immediate operational or financial performance.

Positives

• The grant of stock options aligns the CEO's long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The options do not represent immediate cash value and their ultimate value depends on the future stock price exceeding the exercise price of $1.96.
• The vesting schedule ties a significant portion of the CEO's potential compensation to continued service, which could be seen as a retention mechanism.

Risks

• The vesting of the stock options is subject to the Reporting Person continuing to provide service through each vesting date, meaning forfeiture if service ceases.

Future Outlook

The grant of stock options with a multi-year vesting schedule indicates a long-term incentive structure for the CEO, aligning his future compensation with the company's sustained performance and growth over the coming years.

Industry Context

StockSavvy.ai notes that executive stock option grants are a common and widely accepted practice in the biotechnology and broader corporate sectors. These grants are designed to align the interests of key management personnel with those of shareholders by providing a direct financial incentive for long-term value creation and retention.

Comparison to Industry Standards

• StockSavvy.ai notes that a four-year vesting schedule, with an initial one-year cliff followed by monthly installments, is a common industry standard for executive equity grants. This structure is comparable to practices observed at other publicly traded biotech companies, such as Moderna (MRNA) or BioNTech (BNTX), for similar executive roles, aiming to ensure long-term commitment and performance.

Related Party Transactions

• The grant of 206,000 employee stock options to William Tai-Wei Ho, the CEO, Director, and 10% Owner, constitutes a related party transaction as it involves compensation provided by the company to a key executive and significant shareholder.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's interests with shareholders, potentially leading to better long-term performance. However, future exercise of these options could result in dilution of existing shares.
• Employees: The grant serves as an example of executive compensation, potentially influencing overall compensation philosophy within the company.

Next Steps

• William Tai-Wei Ho must continue to provide service to IN8BIO, INC. for the stock options to vest according to the schedule.

Key Dates

Recommendation

This Form 4 reports a routine executive stock option grant, which is a standard compensation practice. It does not provide new information on the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this as part of ongoing executive incentive structures rather than a catalyst for immediate stock price movement.

Keywords

IN8BIO, INAB, Stock Option, CEO, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Vesting